28 January 2026
28 January 2026
The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.
WHO has called for urgent political and financial commitment from countries to eliminate the disease.
Qilu Pharmaceutical will oversee subsequent development and commercialisation activities.
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
Despite a lacklustre year for UK biotech funding, M&A pickup and trade deals could drive growth rebound.
The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.
As more drugs go subcutaneous, Phillips Medisize's Tony Bedford believes that high-dose biologics will play a growing role for drugmakers.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
